Abstract
A difficulty in the field of gene therapy is the need to increase the susceptibility of hematopoietic stem cells (HSCs) to ex vivo genetic manipulation. To overcome this obstacle a high-throughput screen was performed to identify compounds that could enhance the transduction of target cells by lentiviral vectors. Of the 1280 compounds initially screened using the myeloid-erythroid-leukemic K562 cell line, 30 were identified as possible enhancers of viral transduction. Among the positive hits were known enhancers of transduction (camptothecin, etoposide and taxol), as well as the previously unidentified phorbol 12-myristate 13-acetate (PMA). The percentage of green fluorescent protein (GFP)-positive-expressing K562 cells was increased more than fourfold in the presence of PMA. In addition, the transduction of K562 cells with a lentiviral vector encoding fVIII was four times greater in the presence of PMA as determined by an increase in the levels of provirus in genetically modified cells. PMA did not enhance viral transduction of all cell types (for example, sca-1+ mouse hematopoietic cells) but did enhance viral transduction of human bone marrow-derived CD34+ cells. Notably, the percentage of GFP-positive CD34+ cells was increased from 7% in the absence of PMA to greater than 22% in the presence of 1 nM PMA. PMA did not affect colony formation of CD34+ cells or the expression of the hematopoietic markers CD34 and CD45. These data demonstrate that high-throughput screening can be used to identify compounds that increase the transduction efficiency of lentiviral vectors, identifying PMA as a potential enhancer of lentiviral HSC transduction.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Veres G, Schmidt M, Kutschera I et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009; 326: 818–823.
Boztug K, Schnmidt M, Schwarzer A, Banerjee PP, Díez IA, Dewey RA et al. Stem-cell therapy for Wiskott-Aldrich syndrome. N Engl J Med 2010; 363: 1918–1927.
Cavazzana-Calvo M, Payen E, Negre O, Wang G, Hehir K, Fusil F et al. Transfusion independence and HMGA2 activation after gene therapy of human β-thalasseaemia. Nature 2010; 467: 318–322.
DiGiusto DL, Krishnan A, Li L, Li H, Li S, Rao A et al. RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med 2010; 2: 36–43.
Kumar M, Keller B, Makalou N, Sutton RE Systemic determination of the packaging limit of lentiviral vectors. Hum Gene Ther 2001; 12: 1893–1905.
Yacoub N, Romanowska M, Haritonova N, Foerster J Optimized production and concentration of lentiviral vectors containing large inserts. J Gene Med 2007; 9: 579–584.
Johnston J, Doering CB, Spencer HT Gene therapy strategies incorporating large transgenes. In: Chunsheng Kang(ed) Gene Therapy - Developments and Future Perspectives.. InTech: Croatia, 2011, pp 121–142.
Radcliffe P, Sion CJM, Wilkes EJ, Custard EJ, Beard GL, Kingsman SM et al. Analysis of factor VIII mediated suppression of lentiviral vector titres. Gene Therapy 2008; 15: 289–297.
Lee HJ, Lee YS, Kim HS, Kim YK, Kim JH, Jeon SH et al. Retronectin enhances lentivirus-mediated gene delivery into hematopoietic progenitor cells. Biologicals 2009; 37: 203–209.
Davis BM, Humeau L, Slepushkin V, Binder G, Korshalla L, Ni Y et al. ABC transporter inhibitors that are substrates enhance lentiviral vector transduction into primitive hematopoietic progenitor cells. Blood 2004; 104: 364–373.
Leuci V, Mesiano G, Gammaitoni L, Cammarata C, Capellero S, Todorovic M et al. Transient proteasome inhibition as a strategy to enhance lentiviral transduction of hematopoietic CD34+ cells and T lymphocytes: Implications for the use of low viral doses and large-size vectors. J Biotechnol 2011; 156: 218–226.
Santoni de Sio FR, Cascio P, Zingale A, Gasparini M, Naldini L Proteasome activity restricts lentiviral gene transfer into hematopoietic stem cells and is down-regulated by cytokines that enhance transduction. Blood 2006; 107: 4257–4265.
Millington M, Arndt A, Boyd M, Applegate T, Shen S Towards a clinically relevant transduction protocol for primary human CD34+ hematopoietic stem/progenitor cells. PLoS One 2009; 4: 1–10.
Groeschel B, Bushman F Cell cycle arrest in G2/M promotes early steps of infection by human immunodeficiency virus. J Virol 2005; 79: 5695–5704.
Pommier Y, Leo E, Zhang H, Marchand C DVA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol 2010; 17: 421–433.
Stahelin RV, Wang J, Blatner NR, Rafter JD, Murray D, Cho W The origin of C1A-C2 interdomain interactions in protein kinase Cα. J Biol Chem 2005; 280: 36452–36463.
Steinberg SF Structural basis of protein kinase c isoform function. Phys Rev 2008; 88: 1341–1378.
Papayannopoulou T, Nakamoto B, Yokochi T, Chait A, Kannagi R Human erythroleukemia cell line (HEL) undergoes a drastic macrophage-like shift with TPA. Blood 1983; 62: 832–845.
Doering CB, Gangadharan B, Dukart HZ, Spencer HT Hematopoietic stem cells encoding porcine factor VIII induce pro-coagulant activity in hemophilia A mice with pre-existing factor VIII immunity. Mol Ther 2007; 15: 1093–1099.
Wang CX, Sather BD, Wang X, Adair J, Khan I, Singh S Rapamycin relieves lentiviral vector transduction resistance in human and mouse hematopoietic stem cells. Blood 2014; 124: 913–923.
Kustikova OS, Schiedlmeier B, Brugman MH, Stahlhut M, Bartels S, Li Z et al. Cell-intrinsic and vector-related properties cooperate to determine the incidence and consequences of insertional mutagenesis. Mol Ther 2009; 17: 1537–1547.
Mitchison JM Growth during the cell cycle. Int Rev Cytol 2003; 226: 165–258.
Ono Y, Fujii T, Igarashi K, Kuno T, Tanaka C, Kikkawa U et al. Phorbol ester binding to protein kinase C requires a cysteine-rich zing-finger-like sequence. Proc Natl Acad Sci USA 1989; 86: 4868–4871.
Kazanietz MG, Bustelo XR, Barbacid M, Kolch W, Mischak H, Wong G et al. Zinc finger domains and phorbol ester pharmacophore. Analysis of binding to mutated form of protein kinase C zeta and the vav and c-raf proto-oncogene products. J Biol Chem 1994; 269: 11590–11594.
Kazanietz MG, Barchi JJ Jr, Omichinski JG, Blumberg PM Low affinity binding of phorbol esters to PKC and its cysteine-rich region in the absence of phospholipids. J Biol Chem 1995; 270: 14679–14684.
Quest AF, Bardes ES, Bell RM A phorbol ester binding domain of protein kinase C gamma. Deletion analysis of the Cys2 domain defines a minimal 43-amino acid peptide. J Biol Chem 1994; 269: 2961–2970.
Ron D, Kazanietz MG New insights into the regulation of protein kinase C and novel phorbol ester receptors. FASEB J 1999; 13: 1658–1676.
Kazanietz MG Eyes wide shut: protein kinase C isozymes are not the only receptors for the phorbol ester tumor promoters. Mol Carcinog 2000; 28: 5–11.
Tonn T, Herder C, Becker S, Seifried E, Grez M Generation and characterization of human hematopoietic cell lines expressing factor VIII. J Hematother Stem Cell Res 2002; 11: 695–704.
Warrilow D, Gardner J, Darnell GA, Suhrbier A, Harrich D HIV type 1 inhibiton by protein kinase C modulatory compounds. AIDS Res Hum Retroviruses. 2006; 22: 854–864.
Alexaki A, Quiterio SJ, Liu Y, Irish B, Kilareski E, Nonnemacher MR, Wigdahl B PMA-induced differentiation of a bone marrow progenitor cell line activates HIV-1 LTR-driven transcription. DNA Cell Biol 2007; 26: 387–394.
Strair RK, Schaar D, Goodell L, Aisner J, Chin K, Eid J et al. Administration of a phorbol ester to patients with hematological malignancies: preliminiary results from a phase I clinical trial of 12-O-tetradecanoylphorbol-13-acetate. Clin Cancer Res 2002; 8: 2512–2518.
Johnston J, Denning G, Doering CB, Spencer HT Generation of an optimized lentiviral vector encoding a high-expression factor VIII transgene for gene therapy of hemophilia A. Gene Therapy 2013; 20: 607–615.
Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH Jr . Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet 1995; 10: 119–121.
Gangadharan B, Parker ET, Ide LM, Spencer HT, Doering CB . High-level expression of porcine factor VIII from genetically modified bone marrow-derived stem cells. Blood 2006; 107: 3859–3864.
Spencer HT, Denning G, Gautney RE, Dropulic B, Roy AJ, Baranyi L et al. Lentiviral vector platform for production of bioengineered recombinant coagulation factor VIII. Mol Ther 2011; 19: 302–309.
Doering CB, Healey JF, Parker ET, Barrow RT, Lollar P High level expression of recombinant porcine coagulation factor VIII. J Biol Chem 2002; 277: 38345–38349.
Acknowledgements
We thank Arthur Nienhuis (St Jude University, Memphis, TN, USA) for the SIV vector system. This work was supported by grants from the National Heart, Lung and Blood Institute of the National Institutes of Health.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Johnston, J., Denning, G., Moot, R. et al. High-throughput screening identifies compounds that enhance lentiviral transduction. Gene Ther 21, 1008–1020 (2014). https://doi.org/10.1038/gt.2014.80
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/gt.2014.80
This article is cited by
-
Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy
Journal of Hematology & Oncology (2021)
-
High-Efficiency Transduction of Primary Human Hematopoietic Stem/Progenitor Cells by AAV6 Vectors: Strategies for Overcoming Donor-Variation and Implications in Genome Editing
Scientific Reports (2016)
-
Effects of FVIII immunity on hepatocyte and hematopoietic stem cell–directed gene therapy of murine hemophilia A
Molecular Therapy - Methods & Clinical Development (2016)